Paul W. Hoelscher's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 32,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc - ... | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 32,250 | 32,250 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 9,279 | 9,279 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 73,014 | 73,014 | - | - | Stock Option (Right to Buy) | |
| Reneo Pharmaceuticals Inc | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 6,376 | 6,376 | - | - | Stock Option (right to buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.14 per share. | 20 Apr 2022 | 50,000 | 51,049 (0%) | 0% | 22.1 | 1,107,000 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 50,000 | 36,424 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 114.36 per share. | 20 Apr 2022 | 28,458 | 22,591 (0%) | 0% | 114.4 | 3,254,457 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 115.17 per share. | 20 Apr 2022 | 21,542 | 1,049 (0%) | 0% | 115.2 | 2,480,992 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.01 per share. | 06 Apr 2022 | 215,335 | 1,049 (0%) | 0% | 110.0 | 23,688,788 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.14 per share. | 06 Apr 2022 | 185,060 | 216,384 (0%) | 0% | 22.1 | 4,097,228 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2022 | 185,060 | 86,424 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.01 per share. | 06 Apr 2022 | 91,710 | 66,673 (0%) | 0% | 110.0 | 10,089,026 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.96 per share. | 06 Apr 2022 | 30,275 | 31,324 (0%) | 0% | 16.0 | 483,189 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2022 | 30,275 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Mar 2022 | 172,226 | 172,226 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Mar 2022 | 172,226 | 72,789 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Mar 2022 | 66,626 | 245,015 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Mar 2022 | 66,626 | 1,049 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2022 | 26,090 | 30,275 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 23 Mar 2022 | 26,090 | 1,049 (0%) | 0% | 110.0 | 2,870,002 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.96 per share. | 23 Mar 2022 | 26,090 | 27,139 (0%) | 0% | 16.0 | 416,396 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.01 per share. | 23 Mar 2022 | 11,699 | 160,527 (0%) | 0% | 110.0 | 1,287,018 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 23 Mar 2022 | 1,481 | 159,046 (0%) | 0% | 110 | 162,910 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 23 Mar 2022 | 663 | 158,383 (0%) | 0% | 110 | 72,930 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,558 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,558 | 70,138 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.42 per share. | 21 Jan 2022 | 2,463 | 67,675 (0%) | 0% | 86.4 | 212,852 | Ordinary Shares |
| Reneo Pharmaceuticals Inc | Paul W. Hoelscher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 66,822 | 67,871 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.84 per share. | 04 Jan 2022 | 50,666 | 64,580 (0%) | 0% | 101.8 | 5,159,825 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 47,375 | 115,246 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 17,983 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 14,514 | 14,514 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,642 | 23,286 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,616 | 5,800 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 11,067 | 11,069 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 9,522 | 9,522 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.96 per share. | 28 Dec 2021 | 8,575 | 9,624 (0%) | 0% | 16.0 | 136,857 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 28 Dec 2021 | 8,575 | 1,049 (0%) | 0% | 110 | 943,250 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2021 | 8,575 | 56,365 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2021 | 6,163 | 2,098 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2021 | 6,163 | 178,389 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2021 | 1,049 | 1,049 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 17,418 | 17,418 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 8,708 | 12,119 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 102.50 per share. | 28 Jul 2021 | 3,858 | 8,261 (0%) | 0% | 102.5 | 395,445 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 90.01 per share. | 14 May 2021 | 102,925 | 172,226 (0%) | 0% | 90.0 | 9,263,847 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 17,416 | 17,416 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 4,718 | 4,718 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Feb 2021 | 3,094 | 1,049 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Feb 2021 | 3,094 | 275,151 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 2,358 | 3,407 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.17 per share. | 17 Feb 2021 | 1,045 | 2,362 (0%) | 0% | 87.2 | 91,093 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Jan 2021 | 169,132 | 272,057 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Jan 2021 | 169,132 | 1,049 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2021 | 5,556 | 5,558 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2021 | 5,556 | 6,605 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.43 per share. | 21 Jan 2021 | 2,462 | 4,143 (0%) | 0% | 77.4 | 190,633 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 205,638 | 304,879 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.28 per share. | 04 Jan 2021 | 134,698 | 170,181 (0%) | 0% | 73.3 | 9,870,669 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 98,192 | 99,241 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 65,696 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 34,928 | 34,928 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 17,983 | 17,983 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 14,513 | 29,028 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 75.73 per share. | 24 Aug 2020 | 27,753 | 104,748 (0%) | 0% | 75.7 | 2,101,735 | Ordinary Shares |
| Horizon Therapeutics Plc | Paul W. Hoelscher | EVP, CFO | Sale of securities on an exchange or to another person at price $ 76.23 per share. | 24 Aug 2020 | 1,823 | 102,925 (0%) | 0% | 76.2 | 138,967 | Ordinary Shares |